newsfilter
← Latest News
ACCESS Newswire·

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and